Group 1 - The core focus of the news is the progress of LAE102, a monoclonal antibody developed by the company for the treatment of obesity, with the first patient dosing completed in a Phase I clinical trial in the US [1][2] - The Phase I clinical trial is expected to complete its primary research phase by September 2025, while a multi-dose escalation study is ongoing in China, with preliminary data expected by the end of September 2025 [1] - The company has partnered with Eli Lilly to accelerate the global clinical development of LAE102, retaining global rights to the drug [2] Group 2 - LAE102 targets ActRIIA, a receptor important for muscle regeneration and fat metabolism, showing potential to increase muscle and reduce fat in preclinical models [1] - The combination of LAE102 with GLP-1 receptor agonists may further enhance fat reduction and significantly decrease muscle loss associated with GLP-1 receptor agonist treatment, positioning LAE102 as a high-quality weight control candidate [1]
针对肥胖症治疗 来凯医药（2105.HK）宣布LAE102美国I期临床试验完成首位受试者给药
Ge Long Hui A P P·2025-05-28 00:56